BioSpace News Archive

Dentsply Sirona, Inc., the largest manufacturer of professional dental products and market leader in the dental industry, announced today the launch of Azento™ in the United States.

Saykara, the leading voice and AI-powered virtual assistant for physicians, announced today an investment of $5 million led by SpringRock Ventures, a venture fund focused on the convergence of health care and technology.

Noting World Sepsis Day, Sepset Biosciences Inc., a spin-out company of The Centre for Drug Research and Development (CDRD) in collaboration with Dr. Robert Hancock at The University of British Columbia, is raising awareness about sepsis: a serious medical condition that is the body’s overwhelming and life-threatening response to infection that can lead to tissue damage, organ failure, and death.

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI - Eligible PEA - SME), the pioneer of 2D/3D imaging and data solutions for orthopedics, today announced its consolidated results for the six months ended June 30, 2018, as stated by the Board of Directors on September 12, 2018.

For the fifth year in a row, Tufts Health Plan has received ISO 27001 certification, one of the most rigorous certifications related to information security management.

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against OPKO Health, Inc. (“OPKO” or the “Company) (NASDAQ: OPK) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired OPKO securities between September 26, 2013 and September 7, 2018,

Healthy People 2020 Law and Health Policy Project launches new series with first report focused on nutrition and weight status

The availability of the needle-based Cellvizio platform, now bearing CE mark, could be a game changer for the management of patients with certain pulmonary diseases including lung cancer.

The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

Capital BlueCross has tens of thousands of members who live and work in the Carolinas